Literature DB >> 16939179

Diagnosis and management of endometriosis.

Anne L Mounsey1, Alex Wilgus, David C Slawson.   

Abstract

Signs and symptoms of endometriosis are nonspecific, and an acceptably accurate noninvasive diagnostic test has yet to be reported. Serum markers do not provide adequate diagnostic accuracy. The preferred method for diagnosis of endometriosis is surgical visual inspection of pelvic organs with histologic confirmation. Such diagnosis requires an experienced surgeon because the varied appearance of the disease allows less-obvious lesions to be overlooked. Empiric use of nonsteroidal anti-inflammatory drugs or acetaminophen is a reasonable symptomatic treatment, but the effectiveness of these agents has not been well-studied. Oral contraceptive pills, medroxyprogesterone acetate, and intrauterine levonorgestrel are relatively effective for pain relief. Danazol and various gonadotropin-releasing hormone analogues also are effective but may have significant side effects. There is limited evidence that surgical ablation of endometriotic deposits may decrease pain and increase fertility rates in women with endometriosis. Presacral neurectomy is particularly beneficial in women with midline pelvic pain. Hysterectomy and bilateral salpingo-oophorectomy definitively treat pain from endometriosis at 10 years in 90 percent of patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16939179

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  26 in total

Review 1.  Endometriosis and Chronic Pelvic Pain: Unraveling the Mystery Behind this Complex Condition.

Authors:  Terri Bloski; Roger Pierson
Journal:  Nurs Womens Health       Date:  2008-10

2.  Endometriosis stromal cells induce bone marrow mesenchymal stem cell differentiation and PD-1 expression through paracrine signaling.

Authors:  Peng Chen; Ramanaiah Mamillapalli; Shutaro Habata; Hugh S Taylor
Journal:  Mol Cell Biochem       Date:  2021-01-11       Impact factor: 3.396

3.  Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model.

Authors:  Jaime Kulak; Catha Fischer; Barry Komm; Hugh S Taylor
Journal:  Endocrinology       Date:  2011-05-17       Impact factor: 4.736

Review 4.  Acute small bowel obstruction caused by endometriosis: a case report and review of the literature.

Authors:  Antonella De Ceglie; Claudio Bilardi; Sabrina Blanchi; Massimo Picasso; Marcello Di Muzio; Alberto Trimarchi; Massimo Conio
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

5.  Outcomes of sacral neuromodulation for chronic pelvic pain: a Finnish national multicenter study.

Authors:  A Zegrea; J Kirss; T Pinta; T Rautio; P Varpe; M Kairaluoma; M Aho; C Böckelman; M Lavonius
Journal:  Tech Coloproctol       Date:  2020-01-21       Impact factor: 3.781

6.  Low back pain tied to spinal endometriosis.

Authors:  Zhao Dongxu; Yin Fei; Xiao Xing; Zhang Bo-Yin; Zhu Qingsan
Journal:  Eur Spine J       Date:  2014-02-15       Impact factor: 3.134

7.  The traditional chinese medicine prescription pattern of endometriosis patients in taiwan: a population-based study.

Authors:  Ruei-Chi Fang; Yueh-Ting Tsai; Jung-Nien Lai; Chia-Hao Yeh; Chien-Tung Wu
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-26       Impact factor: 2.629

8.  Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials.

Authors:  Christoph Gerlinger; Ulrike Schumacher; Thomas Faustmann; Antje Colligs; Heinz Schmitz; Christian Seitz
Journal:  Health Qual Life Outcomes       Date:  2010-11-24       Impact factor: 3.186

9.  Dienogest in long-term treatment of endometriosis.

Authors:  Adolf E Schindler
Journal:  Int J Womens Health       Date:  2011-07-06

10.  Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results.

Authors:  Yutaka Osuga; Yoshifumi Seki; Masataka Tanimoto; Takeru Kusumoto; Kentarou Kudou; Naoki Terakawa
Journal:  BMC Womens Health       Date:  2021-06-21       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.